HIGHLIGHTS
- who: Mariano A. Giorgi from the with reduced ejection fraction in Argentina have published the Article: Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina, in the Journal: (JOURNAL)
- what: The study showed that sacubitril/valsartan, compared with both enalapril and ARBs, was a cost-effective alternative in patients with HFrEF. The other approach could be to adjust for discount rates, and this is the one that the authors explore in this paper. Regarding this model, it deserves mention that this situation of being a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.